<DOC>
	<DOCNO>NCT00947661</DOCNO>
	<brief_summary>A single-blind , 12-week , parallel group clinical study plan evaluate efficacy safety SPARC0912 Reference0912 . SPARC0912 experimental drug similar active ingredient contain different preservative Reference0912 . Patients open angle glaucoma ocular hypertension enrol randomly assign receive either product . One drop instill study eye nightly 8:00 PM .</brief_summary>
	<brief_title>Efficacy Safety SPARC0912 Reference0912 Open Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<criteria>Men woman age ≥ 18 year . Diagnosis ocular hypertension ( OHT ) primary open angle glaucoma ( POAG ) . Unmedicated IOP ≥ 22 mmHg one eye . Given inform consent . Women child bear potential practicing acceptable method birth control negative urine pregnancy test . Known lack ocular hypotensive response topical ophthalmic , prostaglandin analog ( opinion investigator ) . Intraocular conventional surgery laser surgery within past six month . Refractive surgery study eye ( e.g. , radial keratotomy , PRK , LASIK , etc . ) within past 3 month . Angle closure glaucoma history acute angle closure treat peripheral iridotomy . Ocular trauma within past 3 month . Progressive retinal optic nerve disease apart glaucoma . Concurrent infectious/non infectious conjunctivitis , keratitis , uveitis either eye . Any abnormality prevent stable applanation tonometry . Use contact lens duration study . Any opacity subject uncooperativeness restricts adequate examination ocular fundus anterior chamber . Clinically significant ocular disease ( e.g. , corneal edema , uveitis , severe keratoconjunctivitis sicca ) might interfere study , include glaucomatous damage severe washout ocular hypotensive medication judge safe . Clinically significant systemic disease might interfere study . History noncompliance medical regimen unwilling comply study protocol . Participation another clinical study within last thirty ( 30 ) day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>glaucoma latanoprost</keyword>
</DOC>